Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EPIX |
---|---|---|
09:32 ET | 357 | 5.81 |
10:03 ET | 172 | 5.875 |
10:26 ET | 100 | 5.82 |
10:35 ET | 243 | 5.804 |
11:29 ET | 100 | 5.6925 |
11:51 ET | 100 | 5.715 |
12:03 ET | 450 | 5.77 |
12:07 ET | 100 | 5.77 |
12:16 ET | 610 | 5.78 |
12:18 ET | 100 | 5.73 |
12:41 ET | 601 | 5.79 |
12:57 ET | 400 | 5.83 |
01:24 ET | 100 | 5.8183 |
01:51 ET | 600 | 5.82 |
01:53 ET | 100 | 5.82 |
02:02 ET | 638 | 5.77 |
03:05 ET | 399 | 5.87 |
03:14 ET | 500 | 5.82 |
03:18 ET | 4681 | 5.73 |
03:21 ET | 100 | 5.73 |
03:25 ET | 100 | 5.72 |
03:30 ET | 200 | 5.72 |
03:38 ET | 300 | 5.755 |
03:39 ET | 100 | 5.76 |
03:41 ET | 524 | 5.795 |
03:43 ET | 100 | 5.79 |
03:45 ET | 100 | 5.81 |
03:48 ET | 100 | 5.81 |
03:50 ET | 500 | 5.84 |
03:52 ET | 800 | 5.825 |
03:54 ET | 1760 | 5.85 |
03:56 ET | 1350 | 5.85 |
03:59 ET | 4579 | 5.82 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ESSA Pharma Inc | 299.5M | -9.3x | --- |
Inozyme Pharma Inc | 298.1M | -3.5x | --- |
Atea Pharmaceuticals Inc | 309.1M | -1.9x | --- |
Q32 Bio Inc | 304.5M | -0.8x | --- |
Solid Biosciences Inc | 317.0M | -2.0x | --- |
Alto Neuroscience Inc | 321.5M | -6.2x | --- |
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $299.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.82 |
EPS | $-0.63 |
Book Value | $3.30 |
P/E Ratio | -9.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.